Aims: To examine the effects of Abn-CBD (GPR55 agonist) and LH-21 (CB1 antagonist) on human and mouse islet function, and to determine signalling via GPR55 using islets from
| INTRODUCTION
Cannabinoids are chemicals produced by the cannabis plant (phytocannabinoids) and vertebrates (endocannabinoids) or manufactured commercially (synthetic cannabinoids), and they all act at cannabinoid G-protein-coupled receptors (GPCRs) to regulate cell function. CB1 and CB2 are the canonical receptors for cannabinoids, whilst another GPCR, GPR55, which has low sequence homology with CB1 and CB2 1 and lacks the typical "cannabinoid binding pocket," 2 is also activated by some cannabinoids. [3] [4] [5] [6] [7] [8] [9] CB1 and GPR55 have in common an abundant expression in the central nervous system and metabolic tissues and a proposed role in energy balance, [10] [11] [12] [13] [14] [15] [16] that may be secondary to their regulation of insulin secretion. 10, 11, 13, 14, 17 We, and others, have
shown that CB1 and GPR55 activation in isolated rodent and human islets is associated with insulinotropic properties, 10, 11, 13, 14, 18 although a shared consensus in the scientific community has still not been reached with respect to the role of CB1 receptors in islets. 19, 20 Some of the discrepancies among studies may arise through lack of specificity of the cannabinoid ligands used. For example, we have
shown that antagonists of CB1 and CB2 have the same stimulatory effects on insulin release from human islets as agonists of these receptors, suggesting that the antagonists act via CB1/CB2-independent pathways. 17 The CB1 antagonist AM251 activates GPR55 [21] [22] [23] and we have recently confirmed that GPR55 is expressed by mouse and human islet β-cells, where it plays a positive role in regulating [Ca 2+ ] i and insulin secretion. 14 In addition, the antiobesity drug rimonabant, which was developed as a CB1 antagonist, also acts as a GPR55 agonist, [21] [22] [23] thus suggesting that its antiobesity and insulin-sensitizing properties might be mediated, at least in part, by activation of this receptor, rather than by antagonizing CB1. 24, 25 LH-21 (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole) ( Figure S1 ) was initially identified through screening of 1,2,4-triazole compounds for cannabinoid receptor activity, and it was found to antagonize the effects of the CB1 agonist WIN 55,212-2. 26 Subsequently, other authors identified LH-21 as a neutral antagonist 24, 27 or weak inverse agonist of CB1 with limited brain penetration, 25 and, similarly to rimonabant, it is reported to have anorexigenic effects in animal models of obesity. 27, 28 Treatment of rats with LH-21 for 10 days resulted in a significant upregulation of GPR55 expression in visceral adipose tissue, suggesting involvement of peripheral GPR55-related regulatory mechanisms in its effects. 27 We have recently demonstrated that LH-21 improves glucose metabolism and reduces anxiety in obese prediabetic mice, this latter effect being prevented by a GPR55 antagonist. 29 Because of the promising therapeutic effects of the phytocannabinoid cannabidiol (CBD),
synthetic CBD derivatives such as abnormal CBD (Abn-CBD; trans-4- Figure S1 ) have been synthesized. 30 Abn-CBD has vasodilator effects that were blocked by the CB1 antagonist SR141716A, but were maintained in CB1/CB2 double knockout mice, which led to the proposal that Abn-CBD acted as an agonist at a novel cannabinoid receptor. 31 Abn-CBD is now considered to be a potent and selective GPR55 agonist. 11 It potentiates glucose-dependent insulin secretion from mouse islets and the BRIN-BD11 cell line in vitro, 11, 13 and improves glucose tolerance in vivo that is associated with increased insulin sensitivity and β-cell proliferation. 11, 13 The importance of GPR55 in promoting proliferation is supported by studies with the GPR55 agonist O-1602 in various cell types, 14, 15, 21, [32] [33] [34] which demonstrated activation of pathways known to regulate β-cell mass. 35, 36 In the present study we investigated the effects of LH-21 and Abn-CBD on the secretory function, apoptosis and proliferation of islets isolated from human non-diabetic donors and C57BL/6 mice.
The availability of islets from GPR55 −/− mice has allowed us to define whether the effects of these compounds on insulin secretion, [Ca 2+ ] i , cAMP, β-cell proliferation and apoptosis are mediated via GPR55-dependent or -independent signalling. 
| MATERIALS AND METHODS

| Materials
| Caspase 3/7 activities
Mouse and human islets were maintained in culture for 24 hours in the absence or presence of 0.1 μM LH-21 or 10 μM Abn-CBD.
Groups of 3 mouse or 5 human islets were then incubated for a further 20 hours in RPMI-1640 or CMRL with 2% FBS (mouse) or 0.2% albumin (human), supplemented with a cytokine cocktail (0.025 U/μL IL-1β, 1 U/μL TNFα, and 1 U/μL IFNγ), and islet cell apoptosis was determined using the Caspase 3/7 Glo assay. (1:10 000) for 1 hour at room temperature and exposed to X-ray film after addition of ECL substrate. 44 
| Statistical analyses
Differences between selected pairs of data were analysed by unpaired Student's t test while differences between several groups were analysed by one-way ANOVA followed by Tukey's, Dunnett's multiple comparison or Newman-Keuls multiple comparison post tests.
3 | RESULTS
| Effects of Abn-CBD and LH-21 on glucoseinduced insulin secretion
As shown in Figure 1A , exposure of human islets to increasing con- Data are expressed as mean + SEM of experiments with islets from 6 separate human donors or 5 independent experiments with mouse islets. ## P < .01 and ### P < .001: response of islets to 20 mM glucose vs 2 mM glucose; *** P < .001 and **** P < .0001 vs secretion in the presence of vehicle (experiments with human islets). ## P < .01 and ### P < .001 response of islets to 20 mM glucose vs 2 mM glucose; ** P < .01 and *** P < .001 secretion from GPR55 +/+ vs GPR55 −/− islets (experiments with mice islets). Data were analysed using unpaired Student's t tests ( Figure 1H,I ). Interestingly, however, it was found that deletion of GPR55 did not abrogate the stimulation of insulin secretion by 1 μM LH-21, and GPR55 −/− islets secreted more insulin than their wild-type counterparts in response to this higher concentration ( Figure 1J ).
Abn-CBD and LH-21 did not significantly stimulate basal insulin secretion from GPR55 +/+ or GPR55 −/− mouse islets ( Figure 1G ,K). ] i and the response to 1 μM LH-21 was sustained 
| Abn-CBD and LH-21 protect islets against cytokine-induced apoptosis via GPR55
GPR55 has been implicated in protecting islets from programmed cell death, 15, 46 thus in the present study caspase 3/7 activities were measured in islets from GPR55 +/+ and GPR55 −/− mice. These experiments indicated that Abn-CBD and LH-21 did not affect basal levels of apoptosis in islets from GPR55 −/− mice but they significantly reduced apoptosis induced by a cytokine cocktail ( Figure 3A) . However, although the cannabinoid ligands exerted protective effects, they did not fully block cytokine-induced apoptosis, which was significantly elevated above basal even in the presence of Abn-CBD or LH-21.
Cytokines also elevated caspase 3/7 activities in islets from GPR55 −/− mice and, while there were small reductions in the presence of Abn-CBD or LH-21, these were not statistically significant ( Figure 3B) . Interestingly, as shown in Figure 3C , Abn-CBD and LH-21 totally reverted cytokine-induced apoptosis in human islets. Abn-CBD to promote β-cell proliferation and increase islet size were independent of any effect on individual β-cell area ( Figure 4E ).
| LH-21 and Abn-CBD stimulate β-cell proliferation
| Effects of Abn-CBD and LH-21 on CREB and AKT phosphorylation in mouse and human islets
Exposure of mouse islets for 30 minutes to 10 μM Abn-CBD or 0.1 μM LH-21 in the presence of 25 mM glucose increased levels of phosphorylated CREB (P-CREB; Figure 5A ), and these ligands also promoted increases in Akt phosphorylation (P-Akt) in mouse islets ( Figure 5B ). Abn-CBD and LH-21 also increased P-AKT in human islets ( Figure 5D ), but in experiments with 4 different batches of human islets they had no effect on P-CREB ( Figure 5C ).
(A) (B) (C) FIGURE 3 Effects of abnormal cannabidiol (Abn-CBD) and LH-21 on mouse and human islet apoptosis. Effects of Abn-CBD and LH-21 on apoptosis of GPR55 +/+ (A) and GPR55 −/− (B) islets and human (C) islets that had been maintained for 20 hours in the absence or presence of a cytokine cocktail. Apoptosis was detected by luminescence assay of caspase 3/7 activities. Data are expressed as mean + SEM of 3 independent experiments for both mouse and human islets, each of 8 to 10 replicates. ** P < .01, *** P < .001, ns P > .05. Data were analysed using one-way ANOVA with repeated measures, followed by Tukey's multiple comparison post test
| DISCUSSION
Despite confirmation of the expression of CB1 and GPR55 by both rodent and human β-cells, 10, 14, 18, 19, 47, 48 the role played by the endocannabinoid system in the modulation of islet secretory activity is still far from being completely understood. For example, while the majority of studies suggest that activation of CB1 receptors increases insulin secretion, 47, [49] [50] [51] others point to the opposite effects. 19, 20 The reasons for the controversies are likely to lie in the experimental models used, the selectivity of the ligands and the difficulties in addressing intracellular coupling where cannabinoid receptors signal via more than one heterotrimeric G-protein. 15, 48 Indeed, various factors such as differences in the concentrations of the agonists and antagonists used, diversities in the experimental design and impact of circulatory factors such as incretins in the in vivo studies, 19 can all contribute to the variability among studies. In the present study we measured insulin release from isolated mouse and human islets under dynamic conditions, where the continuous flow of perifusing buffers minimizes autocrine and paracrine effects of secreted products that may occur in static incubation protocols. 52 In terms of ligand selectivity, it has been shown that some CB1 antagonists, such as AM251
and rimonabant, can also act as agonists for GPR55, 23 which is counterparts. Data were obtained from multiple acquisitions of 45 to 75 islets per condition, each with a minimum of 6 paraffin sections for analysis. Data were analysed using one-way ANOVA, followed by Dunnett's (B) and Newman-Keuls (C-E) multiple comparison post tests expressed by islet β-cells and whose activation increases insulin secretion from both human and mouse islets, 10, 11, 13, 14 and this may have led to differences in interpretation of earlier studies.
Since LH-21, an inverse agonist/neutral antagonist of CB1, shows structural similarities with AM251 and rimonabant, 24, 25, [27] [28] [29] we investigated whether its activation of islet GPR55 could underlie at least some of its reported positive effects on glucose management. 24, [27] [28] [29] An earlier study used a static incubation protocol to show that the CB1 antagonists AM251 and JD-5037 increased insulin release from human islets, 19 and in the present study we
employed perifusion experiments to demonstrate that LH-21 also promoted insulin secretion from human islets. However, we found that the potentiation of insulin release by lower concentrations of LH-21 (1 nM and 0.1 μM) was lost in islets isolated from GPR55
−/− mice, demonstrating that the insulinotropic effects were not secondary to antagonism of islet CB1 receptors, but were a consequence of LH-21 binding to islet GPR55. Thus, these data indicate that caution should be exerted when concluding that the effects evoked by LH-21
are mediated exclusively by CB1, especially when it is used at nanomolar concentrations. Nevertheless, we found that 1 μM LH-21 was able to stimulate insulin secretion after GPR55 deletion, indicating signalling in a GPR55-independent manner at higher concentrations of LH-21.
This stimulatory effect most likely occurs via an undefined receptor, as we previously observed for 10 μM AM251 in human islets. 17 As a parallel investigative strategy we studied the requirement of GPR55 for insulin secretion induced by Abn-CBD, a cannabinoid that is reported to be at least 10-fold more selective for GPR55 than for CB1 or CB2. 16 It has previously been demonstrated that Abn-CBD increases insulin secretion from BRIN-BD11 insulin-secreting cells and mouse islets. 11 In the present study we confirmed that Abn-CBD potentiated glucose-induced insulin secretion from mouse islets and we also demonstrated, for the first time, that it has similar stimulatory effects in human islets. However, despite its reported selectivity as a GPR55 agonist, Abn-CBD stimulated elevations in insulin release in FIGURE 5 Effects of abnormal cannabidiol (Abn-CBD) and LH-21 on CREB and AKT phosphorylation in mouse and human islets. Blotting of mouse (A, B) and human (C, D) islet lysates with antibodies directed against phospho-CREB (P-CREB), CREB, phospho-AKT (P-AKT) and AKT, with the relative densitometric analyses of the immunoreactive proteins normalized as ratios between the phosphorylated and nonphosphorylated forms. Data in the graphs are shown as mean + SEM of 4 independent experiments with mouse and human islets, each with 200 islets per condition. * P < .05, ** P < .01 and *** P < .001. Results were analysed using one-way ANOVA with repeated measures, followed by Dunnett's multiple comparison post test islets from GPR55 −/− mice, indicating that at concentrations of 1 μM and above it exerts GPR55-independent effects in islets. There is a growing body of evidence suggesting that the endocannabinoid system has a role in the regulation of cell proliferation and apoptosis. [57] [58] [59] We have previously reported that CB1 and CB2 agonists protect mouse islets from apoptosis, 60 and we recently demonstrated that LH-21 delivery to pre-diabetic mice has anti-inflammatory and cytoprotective effects. 29 In the present study we showed that LH-21 has direct anti-apoptotic effects in isolated human and mouse islets and the use of islets from GPR55 −/− mice indicated that, as for stimulation of insulin secretion and [Ca 2+ ] i , this was GPR55-mediated. Abn-CBD also possessed anti-apoptotic effects in islets but, in contrast to its GPR55-independent effects on insulin secretion, it failed to significantly protect against cytokine-induced apoptosis in GPR55 −/− islets.
In addition, incubation of isolated islets for 5 days in the presence of 1 μM Abn-CBD or 0.1 μM LH-21 stimulated islet β-cell proliferation.
The beneficial effects of LH-21 were strictly dependent on GPR55.
Abn-CBD-stimulated BrdU incorporation was reduced, but not abolished, in GPR55 −/− islets, indicating that GPR55 is required for some of its pro-proliferative effects but that it acts via another receptor to fully stimulate β-cell mass expansion. Analysis of the untreated islets also indicated that endogenous GPR55 is required for normal maintenance of β-cell mass, since vehicle-treated islets from GPR55 −/− mice had fewer proliferating β-cells, which was associated with decreased numbers of β-cells per islet and reduced islet area.
In terms of identifying signalling cascades by which LH-21 and Abn-CBD can regulate β-cell proliferation and apoptosis, it has been reported that the cannabinoid system can activate the serine/threonine kinase AKT and the transcription factor CREB. 61, 62 Our observations that LH-21 and Abn-CBD stimulated AKT phosphorylation in mouse and human islets support a role for GPR55 signalling via this kinase in islets; however, increased CREB phosphorylation was only observed in mouse islets, suggesting either species-specific signalling downstream of GPR55 or that it might reflect the capacity of the ligands to activate multiple receptors, which may be differentially expressed in mouse and human islets.
In conclusion, the cannabinoid ligands LH-21 and Abn-CBD increase insulin secretion from human and mouse islets, most likely via Ca 2+ -regulated intracellular pathways, protect β-cells from apoptosis and foster increased β-cell proliferation. The use of islets isolated from GPR55 −/− mice allowed the elucidation of the contribution of GPR55-mediated signalling in the functional effects of LH-21 and Abn-CBD and our work provides the first evidence of LH-21 acting as a GPR55 agonist in islets. Furthermore, our data clearly demonstrate that Abn-CBD cannot be considered to be a selective GPR55 agonist, at least in islets.
The ability of LH-21 to potentiate glucose-induced insulin secretion at nanomolar concentrations, its capacity to protect islets from apoptosis and stimulate β-cell proliferation, and its protected profile at the central nervous system level in terms of inducing anxiety/depressive traits 28 suggest that a re-evaluation of this molecule as an active tool for the regulation of glucose management in people with diabetes is warranted.
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